Scilex : Regulation FD Disclosure Form 8 K

Published: 2024-06-21 06:09:10 ET SCLX

Regulation FD Disclosure.

As previously disclosed, on June 11, 2024, Scilex Holding Company (the "Company") entered into that certain Commitment Side Letter with FSF 33433 LLC ("Lender"), pursuant to which Lender is required to provide the Company a non-refundable depositin immediately available funds in the aggregate principal amount of $10 million (the "Deposit").

As of June 21, 2024, the Company has received the full amount of the Deposit from Lender, and has proceeded to make a payment in the aggregate amount of approximately $10.4 million to Oramed Pharmaceuticals Inc. ("Oramed"), representing the remaining amount owed in respect of the June 2024 installment under the senior secured promissory note issued by the Company to Oramed in September 2023.

The information under this Item 7.01 of this Current Report is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

2

Disclaimer

Scilex Holding Company published this content on 21 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2024 10:08:21 UTC.